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In this study, we report a ligand-guided homology modeling approach allowing the analysis
of relevant binding site residue conformations and the identification of two novel histamine
H3 receptor ligands with binding affinity in the nanomolar range. The newly developed
method is based on exploiting an essential charge interaction characteristic for aminergic G-
protein coupled receptors for ranking 3D receptor models appropriate for the discovery of
novel compounds through virtual screening.
Introduction
Virtual screening campaigns are typically classified into ligand-based approaches exploiting
the similarity of molecules to already known active ligands, and structure-based approaches,
where virtual screening models describe three-dimensional chemical interactions between
molecules and the target structure [1]. A literature survey revealed that structure-based
approaches are on average less successful in identifying highly active hits than ligand-based
approaches [2]. However, if active lead compounds are identified, structure-based approaches
hold the information for a subsequent rational optimization of interactions between ligand
and target structure.
Although the amount of publicly available data for ligand-protein complexes is constantly
increasing, structural data is not always available. In this situation researchers often rely on
homology modeling, a method for generating the protein structure of interest based on closely
related proteins with resolved crystal structures [3]. Including ligand information can aid the
homology modeling process and decrease the level of uncertainty by evaluating homology
models to enrich known actives from decoys in docking experiments and/or to allow docking
poses that match data from mutational studies (often termed ‘ligand-based’, ‘ligand-guided’,
‘ligand-steered’ or ‘ligand-supported homology modeling’). Especially G-protein coupled
receptors (GPCRs) were extensively studied using such approaches including serotonin recep-
tors [4], dopamine receptors [5], GABAB receptor [6] and neurokinin receptor 1 [7].
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Most of these approaches heavily depend on scoring algorithms employed by docking pro-
grams to rank ligand poses and to estimate binding affinity [4–6]. However, docking scores
often poorly corelate with binding affinity [8]. Also, searching for or optimizing a single
homology model to bind a diverse set of ligands is arguable, since very different ligands might
bind to or induce different protein conformations [9]. In contrast, Evers and Klebe avoided
the use of docking scores by optimizing a homology model of the neurokinin receptor 1 to
allow interactions with a single ligand that was extensively investigated including structure
activity relationship of the ligand and mutational studies of the receptor to identify interacting
amino acid chains [7]. Though, relying on mutational data can also be misleading, since muta-
tions distant from the protein binding pocket can also drastically affect ligand binding [10].
In this study, we were interested if a single, yet important and reliable interaction can be
exploited in a ligand-guided homology modeling workflow for the histamine H3 receptor
(H3R) to gain structural knowledge about the binding site and to guide the selection of a
homology model for subsequent virtual screening. We focused on an interaction of charged
functional groups between ligands and aminergic GPCRs, which is well characterized and has
been observed in multiple crystal structures of different GPCRs [11,12]. H3R was selected as
target for several reasons: (i) ligand data is publicly available, (ii) crystal structure is currently
still missing, (iii) H3R is an important drug target discussed for many severe diseases including
Alzheimer’s disease, schizophrenia, Parkinson’s disease, narcolepsy, pain, and obesity among
others [13,14] and (iv) a recent study of us revealed that H3R and melanin-concentrating hor-
mone receptor 1 can be inhibited by the same ligand which could be potentially used in obesity
treatment [15]. In this project, 1000 homology models were generated and evaluated for allow-
ing a charged interaction with a defined set of ligands. Best and worst performing models were
structurally investigated and revealed the importance of distinct binding site residue confor-
mations for proper ligand docking. The highest ranked model was used for a pharmacophore-




A template search revealed that the crystal structure of H1R (3RZE [16]) does not show the
highest sequence similarity to H3R. Also, the extracellular loop 2 close to the orthosteric bind-
ing pocket is not resolved in the H1R structure. Hence, homology modeling was performed
with a multiple-template approach employing crystal structures of H1R, muscarinic M2 recep-
tor (M2R) and muscarinic M3 (M3R) receptor to generate 1000 homology models of H3R with
MODELLER 9.15 [17]. The average heavy atom RMSD of 1.2 Å was calculated with VMD
1.9.2 [18], whereat side chain heavy atoms were more flexible (1.6 Å) than backbone heavy
atoms (0.4 Å). A set of 9 antagonists [19] (Table C in S1 File) was chosen to guide the selection
of a homology model for later pharmacophore studies. We were specifically interested into
this ligand series, since we found highly similar molecules active against the melanin-concen-
trating hormone receptor 1 (MCHR1) and dual antagonism of H3R and MCHR1 might pres-
ent a potential treatment option for obesity [15]. Additionally, these ligands are rather big
showing Y-shaped conformations and thus should allow the selection of a homology model
with an open binding pocket able to harbor diverse ligands. Subsequently, models were scored
for presence of a charged interaction between the docked ligands and D3.32 (numbering from
Ballesteros-Weinstein numbering scheme [20]), that is known to be essential for ligand bind-
ing to aminergic GPCRs (Fig 1A) [11]. Docking and scoring have been performed twice to
control for variations introduced by the docking algorithm (Fig B in S1 File). The highest
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ranked model achieved an average score of 0.835 in both docking experiments. This means
that 83.5% of the docking poses allow for a charged interaction with D3.32. The predominant
binding mode of docked ligands involves a charged interaction with D3.32, hydrogen bonds
with D3.32, Y3.33, E5.46 and Y6.51 as well as several hydrophobic contacts (Fig 1B). Interestingly,
we found that 25% of generated models retrieved a score of 0.1 or lower. From these, 7 models
had a score of 0, which means that none of the docking poses was involved in the essential
charged interaction.
Thus, we got interested what determinants could be used to distinguish highly scored mod-
els from poorly scored models. First, 10 best and 10 worst performing models were tested for
geometric errors like phi-psi outliers and heavy atom clashes in MOE 2015 [24] as well as with
homology modeling evaluation programs including VERIFY 3D [25], ERRAT [26] and
PROVE [27]. However, none of the applied methods led to a successful discrimination (Fig C
in S1 File). Next, we analyzed structural differences by comparing the side chain atoms average
position of 10 best and 10 worst performing models (Fig 2). The atom with the highest differ-
ence (4.7 Å) in the average position is a carboxyl oxygen of E5.46 (Fig 2A). In the highly scored
models E5.46 is pointing inside the binding pocket (Fig 2B). This is in line with the predomi-
nant docking pose that is involved in a hydrogen bond with E5.46. In contrast, poorly scored
models show a conformation pointing outside the binding pocket. This conformation is also
energetically unfavorable, since it is pointing toward the lipophilic membrane and no amino
acid with opposite charge is present to compensate the negative charge. The importance of
E5.46 in ligand binding is in agreement with mutational studies [28] and was already described
in previous homology modeling studies for H3R [29,30]. Another atom with a rather high
Fig 1. Ligand-guided homology modeling workflow exploits essential charged interaction known from aminergic GPCRs. (A) Aminergic GPCRs show a common
charge interaction of highly diverse ligands with Aspartate 3.22 as illustrated for Eticlopride co-crystallized with the dopamine D3 receptor (3PBL [21]), Tiotropium co-
crystallized with the muscarinic M4 receptor (5DSG [22]) and Carazolol co-crystallized with the β2 adrenoceptor (5JQH [23]). (B) Predominant binding mode of ligand
series (Table C in S1 File) used for ligand-guided homology modeling. The depicted docking pose of CHEMBL1091834 involves a charged interaction with D3.32¸
hydrogen bonds to D3.32, Y3.33, E5.46 and Y6.51 as well as several hydrophobic contacts. Red arrows–hydrogen bond acceptors, green arrows–hydrogen bond donors, blue
star–positive ionizable, yellow sphere–hydrophobic contact.
https://doi.org/10.1371/journal.pone.0218820.g001
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difference in mean atom position (2.1 Å) is a distal side chain carbon of L7.42. However, we
were not able to draw a clear connection to the docking results.
Virtual screening
The highest scored homology model was used for a screening campaign to identify novel H3R
ligands. 10 diverse antagonists (Table A in S1 File) were docked into the homology model.
Constraints were added to focus on docking poses involved in interactions with the negatively
charged carboxyl-group of D3.32 and E5.46, since all inverse agonists contain at least one posi-
tively charged group. Docking poses with favorable interaction patterns were found for only 5
out of 10 compounds and additionally analyzed to agree with published structure activity rela-
tionship. Derivatives of CHEMBL1923737 (Fig 3, model A) tolerate differently sized pyridone
analogues indicating a location of the pyridone group outside the relatively narrow orthosteric
binding pocket [31]. The literature about CHEMBL2151197 (Fig 3, model B) has only sparse
structure active relationship data [32]. However, later pharmacophore modeling motivated us
to include this docking pose in virtual screening. Analogues of CHEMBL2387294 show that 1
positively charged group can be exchanged by hydrophobic groups without loss of activity
[33]. Hence, a docking pose was chosen that is extending outside the receptor with more space
for different interactions (Fig 3, model C). Data for CHEMBL1269844 report a decrease in
activity when attaching the naphthalene moiety in an extending fashion [34]. Concordantly,
such molecule would lead to clashes with the receptor in the selected binding mode (Fig D
part A in S1 File). The preferred docking pose of the histamine analogue CHEMBL214312 (Fig
D part B in S1 File) is complexed between D3.32 and E5.46 [35]. This binding mode agrees well
with several previous docking studies of histamine [29,30]. Each of the 5 chosen binding poses
is involved in an interaction with charged residues D3.32 and E5.46, which is agreement with the
common binding mode of aminergic GPCRs involving D3.32 and with the importance of E5.46
Fig 2. Best and worst scored homology models show distinct structural differences. Top view onto the orthosteric binding pocket of H3R. Extracellular loop 2 is
not shown for sake of clarity. (A) Structural differences were analyzed by calculating the difference in average side chain atom position of 10 highest and 10 lowest
ranked models. Blue color indicates low difference, yellow high difference. (B) Sidechain conformations of 10 highest and 10 lowest ranked homology models.
Yellow–high ranked models, blue–low ranked models.
https://doi.org/10.1371/journal.pone.0218820.g002
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for proper ligand placement in our homology modeling approach (Fig 2) that is further sup-
ported by mutational data [28] and previous docking studies [29,30]. Docking poses of
CHEMBL1923737, CHEMBL2151197 (Fig 3, model A and B) and CHEMBL1269844 (Fig D
part A in S1 File) only interact with D3.32 despite the already described importance of E5.46 in
ligand binding. However, CHEMBL1923737 has only a single moiety able to act as hydrogen
bond donor. Thus, it can only interact with one of such residues. Additionally, mutational data
from the histamine H1 receptor suggests that the amino acid at position 5.46 is only important
for some ligands [36,37]. Selected complexes were minimized using SZYBKI [38] to allow
binding site adaptation to the docked ligand. Pharmacophores were created and iteratively
optimized using actives and property-matched decoys generated with DUD-E [39]. Three
pharmacophores were found to efficiently discriminate between actives and decoys (Fig 3, Fig
E in S1 File). Only pharmacophore model C includes interactions with residue E5.46, whose
conformation was found to be important for proper ligand docking in prior homology model-
ing selection. However, the 10 diverse inverse agonists used for this docking differ significantly
from the shape of the Y-shaped compounds employed in ligand-guided homology modeling.
Thus, it is not surprising that binding modes and interaction partners are to some extent
different.
Fig 3. Virtual screening workflow results in 8 compounds out of 1.4 M for in-vitro validation. Workflow for virtual screening using 3 different pharmacophores
based on docking poses of CHEMBL1923737 (model A), CHEMBL2151197 (model B) and CHEMBL2387294 (model C). Model A led to identification of
compounds 3, 5, 6, 8, 9, model B to compounds 4, 7 and model C to compounds 1, 2, 10 (Fig 4, Table E in S1 File). � compounds 9 and 10 (model A and C) were
removed from experimental testing due to insufficient purity as determined by LC-MS. Red arrows–hydrogen bond acceptors, green arrows–hydrogen bond
donors, blue star–positive ionizable, yellow sphere–hydrophobic contact.
https://doi.org/10.1371/journal.pone.0218820.g003
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These pharmacophore models were used to screen a library of 1.4 M commercially available
compounds (Enamine Ltd., Kyiv, Ukraine, www.enamine.net) resulting in almost 16,000 hits.
The hits were docked into the respective minimized homology model and resulting docking
poses were assessed for matching the previously screened pharmacophores. This procedure
yielded 73 hits, which were visually inspected to identify hits complementing the receptor
binding pocket surface. To broaden the chemical space of H3R ligands, hits were also priori-
tized to cover positive ionizable head groups that are underrepresented or completely absent
in the H3R ligand data of the CHEMBL 20 database [40], i.e. terminal guanidino, 2,2,6,6-tetra-
methylpiperidino and secondary amino group (Fig 4). In total, 10 compounds were purchased
for in-vitro testing. However, two compounds had to be excluded due to insufficient purity as
determined by LC-MS (Table E in S1 File).
Two molecules (5 and 6) were found to bind H3R in nanomolar concentration ranges (Fig
5). The identified binding mode indicates very similar interaction patterns including a charged
interaction to D3.32, hydrogen bonds to D3.32 and Y3.33 as well as several hydrophobic contacts.
Moreover, we observed pi-cation interactions to D3.32 and Y3.33. Compound 6 shows an addi-
tional pi-cation interaction to F7.39 which may contribute to its superior activity towards H3R
compared to compound 5. Closest H3R ligand analogues in CHEMBL 24 [40] were identified
by employing Morgan fingerprints [41] implemented in RDKit [42] nodes for KNIME [43]
with a Tanimoto score of 0.53 for compound 5 and of 0.36 for compound 6 (Fig 4). The closest
analogues were characterized as inverse agonists indicating the same mode of action for the
newly identified compounds 5 and 6 [44,45]. According to Morgan fingerprints [41] both
compounds significantly differ from CHEMBL1923737 whose docking pose was used for
pharmacophore modeling (Table D in S1 File). This is in line with frequently observed scaffold
hopping in pharmacophore screening campaigns [46]. The thiazole motif of compound 5 has
recently also been incorporated in new lead findings for this receptor subtype [47]. Compound
6 is known as CHEMBL1433079 and was tested in different high throughput bioassays. How-
ever, none of the reported primary screen activities was further investigated hindering a proper
assessment of the data.
The remaining compounds bound H3R at a concentration of 10 μM less than 50% and were
not considered for in-depth activity characterization (Fig 4). Compounds 1–4 and 7 represent
a molecule class that does not carry a lipophilic moiety (e.g. ethyl, cyclopropyl) at the charged
head group like in compound 5 and 6 indicating an important role of this structural feature.
Compound 8 does carry such hydrophobic moiety at the positively charged amine but was
also found to be inactive. Hence, we speculate that the methyl group might be too small to
effectively fulfill this structural role.
Conclusion
In this study, we successfully applied a ligand-guided homology modeling workflow to H3R.
Therefore, 1000 homology models were generated and evaluated for allowing a charged inter-
action in ligand docking experiments. A structural analysis of best and worst performing mod-
els revealed an important conformation of the binding site residue E5.46 that is critical for
proper ligand placement by the docking program. The best performing model was subse-
quently used in a virtual screening campaign and resulted in the identification of 2 novel H3R
ligands scaffolds with nanomolar affinity. Although successful, we do not claim that the best
performing model is necessarily the most realistic one. However, we could show that many
models were generated that allowed none or only few docking poses with the characteristic
charged interaction. Thus, a single, easy-to-handle descriptor could be used to eliminate many
low-quality homology models from further analysis.
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Experimental section
Preparation of ligand data
The following workflow was conducted in KNIME [43] if not specified else. Histamine H3
receptor (H3R) ligand data was retrieved from Chembl 20 [40] database and filtered for
Fig 4. In-vitro validation of virtual screening hits identified 2 novel nanomolar H3R ligands. Activity results of radioligand depletion assay against H3R. Ki data
is presented as mean values calculated from at least three independent experiments, each performed in triplicates. aCHEMBL1172076 with Tanimoto score of 0.53
when comparing with compound 5 using Morgan fingerprints, bCHEMBL180478 with Tanimoto score of 0.36 when comparing with compound 6 using Morgan
fingerprints.
https://doi.org/10.1371/journal.pone.0218820.g004
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molecular weight (� 500 Da), confidence score (= 9), standard activity type (Ki, Kd, IC50 or
EC50), standard relation (=), standard activity value (� 10) and standard activity unit (nM).
Ligands with unclarified stereo centers were removed with a combination of RDKit [42] and
Indigo [48] nodes. If multiple activities were available for a single ligand, binding data (Ki, Kd)
was preferred over functional data IC50 or EC50) and more recent data was preferred over
older data. The literature of the remaining compounds was checked to remove agonists result-
ing in a final set of 632 inverse agonists. From this set 10 diverse inverse agonists (Table A in
S1 File) were selected using the RDKit diversity picker based on MorganFeat fingerprints [41]
(diameter = 4). This set was used for docking experiments to generate pharmacophores. Addi-
tionally, 100 diverse inverse agonists were selected for pharmacophore validation. Further-
more, the 100 diverse inverse agonists were used to generate decoys using the DUD-E decoy
generator [39] for pharmacophore validation. The decoy set contains 3051 unique molecules.
3D coordinates of all molecules used in this study were generated and energetically minimized
with the MMFF94s [49] force field using RDKit nodes[42]. Hydrogens were added, strong
acids deprotonated and strong bases protonated by using the molecule wash function in MOE
2015 [24].
Homology modeling
The amino acid sequence of human H3R was retrieved from Uniprot [50] (Q9Y5N1) and
employed for a homology model template search in the PDB[51] using the BLAST algorithm
[52]. Structure files of the top ranked templates in the inactive conformation were used for an
alignment in MOE 2015 [24]. Surprisingly, the crystal structure of H1R (3RZE [16]) did not
show the highest sequence similarity to H3R. Also, the extracellular loop 2 (ECL2) close to the
orthosteric binding pocket is not resolved in the H1R structure. Hence, homology modeling
was performed with a multiple-template approach. MODELLER 9.15 [17] was used to generate
1000 homology models using H1R (3RZE [16]), muscarinic M2 receptor (M2R, 3UON [53])
and muscarinic M3 receptor (M3R, 4U15 [54]) as templates. Since ECL2 is not completely
resolved in the H1R structure (3RZE), unresolved ECL2 parts were built by MODELLER solely
based on M2R (3UON) and M3R (4U15). The sequence alignment as well as changed parame-
ters of MODELLER functions can be found in the supporting information (Fig A and Table B
in S1 File).
Fig 5. Potential binding modes of active ligands are very similar. Observed interaction of screening hits 5 (A) and 6 (B). Red arrows–hydrogen bond acceptors, green
arrows–hydrogen bond donors, blue star–positive ionizable, yellow sphere–hydrophobic contact.
https://doi.org/10.1371/journal.pone.0218820.g005
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Docking experiments
A set of 9 inverse agonists [19] (Table C in S1 File) was chosen to guide the homology model
selection and docked into all homology models using GOLD 5.2 [55] with default settings if
not specified otherwise. The active site was defined by residues that are known from other ami-
nergic GPCRs to be involved in ligand binding (D3.32, Y3.33, Y4.56, E5.46, W6.48, Y6.51 and P7.39)
[11]. 10 conformations were generated per molecule with the genetic algorithm set to ’Library
Screening’. Early termination was disabled resulting in 90 conformations per homology
model. Docking results were analyzed for ionic interaction between the ligand and D3.32 that is
characteristic for aminergic GPCRs [11]. Less or equal than 6 Å between the carbon atom of
the carboxyl group of D3.32 and the positively charged amine of the ligand was considered to
be sufficient for ionic interaction. Docking and scoring have been performed to twice to con-
trol for variation introduced by the docking algorithm (Fig B in S1 File).
Homology model evaluation
10 best and 10 worst performing models were tested for geometric errors like phi-psi outliers
and heavy atom clashes in MOE 2015 [24] as well as with homology modeling evaluation pro-
grams including VERIFY 3D [25], ERRAT [26] and PROVE [27]. No statistically significant
difference was found (Fig C in S1 File).
Pharmacophore generation
The 10 diverse H3R inverse agonists generated as described above were docked into the
selected homology model using GOLD 5.2 [55] with default settings if not specified otherwise.
The active site was defined by residues that are known from other aminergic GPCRs to be
involved in ligand binding(D3.32, Y3.33, Y4.56, E5.46, W6.48, Y6.51 and P7.39) [11]. 10 conforma-
tions were generated per molecules with flip ring corners, flip pyramidal N and generate
diverse solutions settings enabled and early termination setting disabled. Protein HBond con-
straints with a constraint weight of 10 and a minimum H-bond geometry weight of 0.005 were
added to focus on conformations involving hydrogen bonds to carboxyl oxygens of D3.32 and
E5.46, since all docked ligands contain a positively charged group that should interact with neg-
atively charged carboxyl-group of D3.32 or E5.42. Docking results were analyzed in LigandScout
3.12 [56] for interactions explaining the structure-activity relationship. Selected complexes
were minimized using Szybki 1.8.0.1 [38] with the MMFF94s forcefield and the Poisson-Boltz-
mann model. Sidechains within 10 Åwere set flexible to allow adaption of the binding site resi-
dues to the docked ligand. LigandScout 3.12 was used to generate pharmacophores of the
minimized complexes. Default pharmacophores generated with LigandScout 3.12 were opti-
mized against a set of 100 diverse active inverse agonists and 3051 decoys by removing features
or increasing the tolerance radius of selected features if supported by the structure activity rela-
tionship. Three pharmacophores were found to successfully discriminate between actives and
decoys according to receiver operating characteristic curves (Fig E in S1 File).
Virtual screening and selection
The three selected pharmacophores were employed to screen a library of 1464080 molecules
(Enamine Ltd., Kyiv, Ukraine, www.enamine.net) using LigandScout 3.12 [56] resulting in
15965 hits. These hits were redocked into the respective minimized model using GOLD 5.2
with default settings if not specified otherwise. The active site was defined by residues that are
known from other aminergic GPCRs to be involved in ligand binding (D3.32, Y3.33, Y4.56, E5.46,
W6.48, Y6.51 and P7.39) [11]. 10 conformations were generated per molecules with flip ring
Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligands
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corners, flip pyramidal N and generate diverse solutions settings enabled. The redocked poses
were scored to match the features of the respective pharmacophore model resulting in 73 hits.
This set was visually inspected, and 10 molecules were selected for purchase. Ordered com-
pounds were analyzed for purity with LC-MS leading to exclusion of 2 molecules from further
analysis. The 8 remaining molecules possess purities of at least 95% and were tested in-vitro
for activity against H3R (Table E in S1 File).
In-vitro experiments
Radioligand depletion assays were performed as described previously using crude hH3R mem-
brane extracts obtained from HEK-293 cells stably expressing the hH3R [15,57]. Briefly, crude
membrane extracts were incubated with various concentrations of test ligands (between 0.01
nM and 100 μM) and [3H]-N-alpha-methylhistamine. Bound radioligand were harvested
through GF/B filters and measured using liquid scintillation counting. Data analysis were per-
formed with GraphPad Prism 6 using non-linear regression. The Ki values for each experi-
ment were obtained according to Cheng-Prusoff and converted to pKi values to allow
statistical analysis. Mean values were calculated from at least three independent experiments,
each performed in triplicates (Table E in S1 File).
Supporting information




We thank Gina Alpert for excellent technical assistance. We would like to thank the Elsa-Neu-
mann-Foundation for financial support of DS.
Author Contributions
Conceptualization: David Schaller, Gerhard Wolber.
Investigation: David Schaller, Stefanie Hagenow, Holger Stark.
Methodology: David Schaller.
Resources: Gerhard Wolber.
Software: David Schaller, Gerhard Wolber.
Writing – original draft: David Schaller, Holger Stark.
Writing – review & editing: Holger Stark, Gerhard Wolber.
References
1. Lavecchia A, Giovanni C. Virtual Screening Strategies in Drug Discovery: A Critical Review. Curr Med
Chem. 2013; 20: 2839–2860. https://doi.org/10.2174/09298673113209990001 PMID: 23651302
2. Ripphausen P, Nisius B, Peltason L, Bajorath J. Quo Vadis, Virtual Screening? A Comprehensive Sur-
vey of Prospective Applications. J Med Chem. 2010; 53: 8461–8467. https://doi.org/10.1021/
jm101020z PMID: 20929257
3. Schmidt T, Bergner A, Schwede T. Modelling three-dimensional protein structures for applications in
drug design. Drug Discov Today. 2014; 19: 890–897. https://doi.org/10.1016/j.drudis.2013.10.027
PMID: 24216321
Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligands
PLOS ONE | https://doi.org/10.1371/journal.pone.0218820 June 25, 2019 10 / 13
4. Rodrı´guez D, Ranganathan A, Carlsson J. Strategies for improved modeling of GPCR-drug complexes:
Blind predictions of serotonin receptors bound to ergotamine. J Chem Inf Model. 2014; 54: 2004–2021.
https://doi.org/10.1021/ci5002235 PMID: 25030302
5. Kołaczkowski M, Bucki A, Feder M, Pawłowski M. Ligand-Optimized Homology Models of D 1 and D 2
Dopamine Receptors: Application for Virtual Screening. J Chem Inf Model. 2013; 53: 638–648. https://
doi.org/10.1021/ci300413h PMID: 23398329
6. Freyd T, Warszycki D, Mordalski S, Bojarski AJ, Sylte I, Gabrielsen M. Ligand-guided homology model-
ling of the GABAB2 subunit of the GABAB receptor. PLoS One. 2017; 12: e0173889. https://doi.org/10.
1371/journal.pone.0173889 PMID: 28323850
7. Evers A, Klebe G. Successful Virtual Screening for a Submicromolar Antagonist of the Neurokinin-1
Receptor Based on a Ligand-Supported Homology Model. J Med Chem. 2004; 47: 5381–5392. https://
doi.org/10.1021/jm0311487 PMID: 15481976
8. Warren GL, Andrews CW, Capelli A-M, Clarke B, LaLonde J, Lambert MH, et al. A critical assessment
of docking programs and scoring functions. J Med Chem. 2006; 49: 5912–31. https://doi.org/10.1021/
jm050362n PMID: 17004707
9. Teague SJ. Implications of protein flexibility for drug discovery. Nat Rev Drug Discov. 2003; 2: 527–541.
https://doi.org/10.1038/nrd1129 PMID: 12838268
10. Ragland DA, Whitfield TW, Lee S-K, Swanstrom R, Zeldovich KB, Kurt-Yilmaz N, et al. Elucidating the
Interdependence of Drug Resistance from Combinations of Mutations. J Chem Theory Comput. 2017;
13: 5671–5682. https://doi.org/10.1021/acs.jctc.7b00601 PMID: 28915040
11. Michino M, Beuming T, Donthamsetti P, Newman AH, Javitch JA, Shi L. What can crystal structures of
aminergic receptors tell us about designing subtype-selective ligands? Pharmacol Rev. 2015; 67: 198–
213. https://doi.org/10.1124/pr.114.009944 PMID: 25527701
12. Nikolic K, Agbaba D, Stark H. Pharmacophore modeling, drug design and virtual screening on multi-tar-
geting procognitive agents approaching histaminergic pathways. J Taiwan Inst Chem Eng. 2015; 46:
15–29. https://doi.org/10.1016/j.jtice.2014.09.017
13. Berlin M, Boyce CW, De Lera Ruiz M. Histamine H3 receptor as a drug discovery target. J Med Chem.
2011; 54: 26–53. https://doi.org/10.1021/jm100064d PMID: 21062081
14. Khanfar MA, Affini A, Lutsenko K, Nikolic K, Butini S, Stark H. Multiple Targeting Approaches on Hista-
mine H3 Receptor Antagonists. Front Neurosci. 2016; 10: 1–17. https://doi.org/10.3389/fnins.2016.
00001d>
15. Schaller D, Hagenow S, Alpert G, Naß A, Schulz R, Bermudez M, et al. Systematic Data Mining Reveals
Synergistic H3R/MCHR1 Ligands. ACS Med Chem Lett. 2017; 8: 648–53. https://doi.org/10.1021/
acsmedchemlett.7b00118 PMID: 28626527
16. Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V, et al. Structure of the human
histamine H1 receptor complex with doxepin. Nature. 2011; 475: 65–70. https://doi.org/10.1038/
nature10236 PMID: 21697825
17. Webb B, Sali A. Comparative Protein Structure Modeling Using MODELLER. Curr Protoc Bioinforma.
2016; 54: 5.6.1–5.6.37. https://doi.org/10.1002/cpbi.3 PMID: 27322406
18. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996; 14: 33–8, 27–
8. https://doi.org/10.1016/0263-7855(96)00018-5 PMID: 8744570
19. Berlin M, Lee YJ, Boyce CW, Wang Y, Aslanian R, McCormick KD, et al. Reduction of hERG inhibitory
activity in the 4-piperidinyl urea series of H3 antagonists. Bioorg Med Chem Lett. 2010; 20: 2359–64.
https://doi.org/10.1016/j.bmcl.2010.01.121 PMID: 20188550
20. Ballesteros JA, Weinstein H. [19] Integrated methods for the construction of three-dimensional models
and computational probing of structure-function relations in G protein-coupled receptors. Methods Neu-
rosci. 1995; 25: 366–428. https://doi.org/10.1016/S1043-9471(05)80049-7
21. Chien EYT, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, et al. Structure of the human dopamine
D3 receptor in complex with a D2/D3 selective antagonist. Science. 2010; 330: 1091–5. https://doi.org/
10.1126/science.1197410 PMID: 21097933
22. Thal DM, Sun B, Feng D, Nawaratne V, Leach K, Felder CC, et al. Crystal structures of the M1 and M4
muscarinic acetylcholine receptors. Nature. 2016; 531: 335–340. https://doi.org/10.1038/nature17188
PMID: 26958838
23. Staus DP, Strachan RT, Manglik A, Pani B, Kahsai AW, Kim TH, et al. Allosteric nanobodies reveal the
dynamic range and diverse mechanisms of G-protein-coupled receptor activation. Nature. 2016; 535:
448–52. https://doi.org/10.1038/nature18636 PMID: 27409812
24. Chemical Computing Group Inc. Molecular Operating Environment (MOE). Montreal, QC, Canada;
2015. pp. 1010 Sherbooke St. West, Suite #910.
Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligands
PLOS ONE | https://doi.org/10.1371/journal.pone.0218820 June 25, 2019 11 / 13
25. Lu¨thy R, Bowie JU, Eisenberg D. Assessment of protein models with three-dimensional profiles. Nature.
1992; 356: 83–5. https://doi.org/10.1038/356083a0 PMID: 1538787
26. Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions.
Protein Sci. 1993; 2: 1511–9. https://doi.org/10.1002/pro.5560020916 PMID: 8401235
27. Pontius J, Richelle J, Wodak SJ. Deviations from standard atomic volumes as a quality measure for pro-
tein crystal structures. J Mol Biol. 1996; 264: 121–36. https://doi.org/10.1006/jmbi.1996.0628 PMID:
8950272
28. Uveges AJ, Kowal D, Zhang Y, Spangler TB, Dunlop J, Semus S, et al. The role of transmembrane
helix 5 in agonist binding to the human H3 receptor. J Pharmacol Exp Ther. 2002; 301: 451–8. Avail-
able: http://www.ncbi.nlm.nih.gov/pubmed/11961043 https://doi.org/10.1124/jpet.301.2.451 PMID:
11961043
29. Kiss R, KeserűGM. Structure-based discovery and binding site analysis of histamine receptor ligands.
Expert Opin Drug Discov. Taylor & Francis; 2016; 11: 1165–1185. https://doi.org/10.1080/17460441.
2016.1245288 PMID: 27704986
30. Kooistra AJ, Kuhne S, de Esch IJP, Leurs R, de Graaf C. A structural chemogenomics analysis of ami-
nergic GPCRs: lessons for histamine receptor ligand design. Br J Pharmacol. 2013; 170: 101–126.
https://doi.org/10.1111/bph.12248 PMID: 23713847
31. Becknell NC, Lyons JA, Aimone LD, Gruner JA, Mathiasen JR, Raddatz R, et al. Synthesis and evalua-
tion of pyridone-phenoxypropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists.
Bioorg Med Chem Lett. 2011; 21: 7076–80. https://doi.org/10.1016/j.bmcl.2011.09.091 PMID:
22014551
32. Wager TT, Pettersen BA, Schmidt AW, Spracklin DK, Mente S, Butler TW, et al. Discovery of two clini-
cal histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]
cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phe-
nyl]-N-(2-methylpropyl)cyclobuta. J Med Chem. 2011; 54: 7602–20. https://doi.org/10.1021/jm200939b
PMID: 21928839
33. Gao Z, Hurst WJ, Guillot E, Czechtizky W, Lukasczyk U, Nagorny R, et al. Discovery of aryl ureas and
aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (Part
I). Bioorganic Med Chem Lett. Elsevier Ltd; 2013; 23: 3416–3420. https://doi.org/10.1016/j.bmcl.2013.
03.080 PMID: 23591110
34. Anderson JT, Campbell M, Wang J, Brunden KR, Harrington JJ, Stricker-Krongrad A, et al. Investiga-
tion of 4-piperidinols as novel H3 antagonists. Bioorg Med Chem Lett. 2010; 20: 6246–9. https://doi.org/
10.1016/j.bmcl.2010.08.099 PMID: 20833043
35. Watanabe M, Kazuta Y, Hayashi H, Yamada S, Matsuda A, Shuto S. Stereochemical diversity-oriented
conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists
with an imidazolylcyclopropane structure. J Med Chem. 2006; 49: 5587–96. https://doi.org/10.1021/
jm0603318 PMID: 16942032
36. Moguilevsky N, Varsalona F, Guillaume JP, Noyer M, Gillard M, Daliers J, et al. Pharmacological and
functional characterisation of the wild-type and site-directed mutants of the human H1 histamine recep-
tor stably expressed in CHO cells. J Recept Signal Transduct Res. 15: 91–102. https://doi.org/10.3109/
10799899509045210 PMID: 8903934
37. Bruysters M, Pertz HH, Teunissen A, Bakker RA, Gillard M, Chatelain P, et al. Mutational analysis of the
histamine H1-receptor binding pocket of histaprodifens. Eur J Pharmacol. 2004; 487: 55–63. https://doi.
org/10.1016/j.ejphar.2004.01.028 PMID: 15033376
38. SZYBKI 1.8.0.1: OpenEye Scientific Software, Santa Fe, NM; http://www.eyesopen.com.
39. Mysinger MM, Carchia M, Irwin JJ, Shoichet BK. Directory of Useful Decoys, Enhanced (DUD-E): Better
Ligands and Decoys for Better Benchmarking. J Med Chem. 2012; 55: 6582–6594. https://doi.org/10.
1021/jm300687e PMID: 22716043
40. Bento AP, Gaulton A, Hersey A, Bellis LJ, Chambers J, Davies M, et al. The ChEMBL bioactivity data-
base: An update. Nucleic Acids Res. 2014; 42. https://doi.org/10.1093/nar/gkt1031 PMID: 24214965
41. Rogers D, Hahn M. Extended-connectivity fingerprints. J Chem Inf Model. 2010; 50: 742–754. https://
doi.org/10.1021/ci100050t PMID: 20426451
42. RDKit: Open-source cheminformatics; http://www.rdkit.org.
43. Berthold MR, Cebron N, Dill F, Gabriel TR, Ko¨tter T, Meinl T, et al. KNIME: The Konstanz Information
Miner. 2008. pp. 319–326. https://doi.org/10.1007/978-3-540-78246-9_38
44. Zaragoza F, Stephensen H, Peschke B, Rimvall K. 2-(4-Alkylpiperazin-1-yl)quinolines as a New Class
of Imidazole-Free Histamine H 3 Receptor Antagonists. J Med Chem. 2005; 48: 306–311. https://doi.
org/10.1021/jm040873u PMID: 15634025
Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligands
PLOS ONE | https://doi.org/10.1371/journal.pone.0218820 June 25, 2019 12 / 13
45. Letavic MA, Aluisio L, Atack JR, Bonaventure P, Carruthers NI, Dugovic C, et al. Pre-clinical characteri-
zation of aryloxypyridine amides as histamine H3 receptor antagonists: Identification of candidates for
clinical development. Bioorg Med Chem Lett. 2010; 20: 4210–4214. https://doi.org/10.1016/j.bmcl.
2010.05.041 PMID: 20561786
46. Schneider Neidhart, Giller Schmid. “Scaffold-Hopping” by Topological Pharmacophore Search: A Con-
tribution to Virtual Screening. Angew Chem Int Ed Engl. 1999; 38: 2894–2896. Available: http://www.
ncbi.nlm.nih.gov/pubmed/10540384 PMID: 10540384
47. Khanfar MA, Reiner D, Hagenow S, Stark H. Design, synthesis, and biological evaluation of novel oxa-
diazole- and thiazole-based histamine H 3 R ligands. Bioorg Med Chem. Elsevier; 2018; 26: 4034–
4046. https://doi.org/10.1016/j.bmc.2018.06.028 PMID: 29960729
48. Pavlov D, Rybalkin M, Karulin B, Kozhevnikov M, Savelyev A, Churinov A. Indigo: universal cheminfor-
matics API. J Cheminform. 2011; 3: P4. https://doi.org/10.1186/1758-2946-3-S1-P4
49. Halgren TA. MMFF VI. MMFF94s option for energy minimization studies. J Comput Chem. 1999; 20:
720–729. https://doi.org/10.1002/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X
50. Consortium UniProt. UniProt: a hub for protein information. Nucleic Acids Res. 2015; 43: D204–12.
https://doi.org/10.1093/nar/gku989 PMID: 25348405
51. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank.
Nucleic Acids Res. 2000; 28: 235–42. https://doi.org/10.1093/nar/28.1.235 PMID: 10592235
52. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol.
1990; 215: 403–410. https://doi.org/10.1016/S0022-2836(05)80360-2 PMID: 2231712
53. Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M, Zhang C, et al. Structure of the human
M2 muscarinic acetylcholine receptor bound to an antagonist. Nature. 2012; 482: 547–51. https://doi.
org/10.1038/nature10753 PMID: 22278061
54. Thorsen TS, Matt R, Weis WI, Kobilka BK. Modified T4 Lysozyme Fusion Proteins Facilitate G Protein-
Coupled Receptor Crystallogenesis. Structure. 2014; 22: 1657–64. https://doi.org/10.1016/j.str.2014.
08.022 PMID: 25450769
55. Cole J, Willem M. Nissink J, Taylor R. Protein-Ligand Docking and Virtual Screening with GOLD. In:
Alvarez J, Shoichet B, editors. Virtual Screening in Drug Discovery. Boca Raton: Taylor & Francis
CRC Press; 2005. pp. 379–415. https://doi.org/10.1201/9781420028775.ch15
56. Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their
use as virtual screening filters. J Chem Inf Model. 2005; 45: 160–9. https://doi.org/10.1021/ci049885e
PMID: 15667141
57. Kottke T, Sander K, Weizel L, Schneider EH, Seifert R, Stark H. Receptor-specific functional efficacies
of alkyl imidazoles as dual histamine H3/H4 receptor ligands. Eur J Pharmacol. 2011; 654: 200–8.
https://doi.org/10.1016/j.ejphar.2010.12.033 PMID: 21237145
Ligand-guided homology modeling drives identification of novel histamine H3 receptor ligands
PLOS ONE | https://doi.org/10.1371/journal.pone.0218820 June 25, 2019 13 / 13
